FY2027 EPS Estimates for Intellia Therapeutics, Inc. Cut by Analyst (NASDAQ:NTLA)

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Brookline Capital Management cut their FY2027 earnings estimates for shares of Intellia Therapeutics in a research report issued on Thursday, August 8th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of $22.05 per share for the year, down from their prior forecast of $22.39. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($4.98) per share. Brookline Capital Management also issued estimates for Intellia Therapeutics’ FY2028 earnings at $48.95 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. The firm’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.40) EPS.

Other analysts also recently issued research reports about the stock. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a research report on Thursday, June 27th. BMO Capital Markets lifted their price objective on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Finally, JPMorgan Chase & Co. cut their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $61.58.

Intellia Therapeutics Trading Up 2.9 %

Shares of NTLA stock opened at $22.41 on Monday. Intellia Therapeutics has a 1-year low of $19.37 and a 1-year high of $39.14. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -4.11 and a beta of 1.81. The stock has a 50-day moving average of $24.22 and a 200-day moving average of $25.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Blue Trust Inc. increased its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares in the last quarter. Signaturefd LLC raised its holdings in Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after buying an additional 751 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after buying an additional 472 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after buying an additional 2,459 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in shares of Intellia Therapeutics by 35.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after acquiring an additional 793 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.